Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutations

被引：0
|
作者：
Wu, L. [1 ]
Pu, X. [2 ]
Zhou, Y. [2 ]
Kong, Y. [2 ]
Chen, B. [2 ]
Yang, A. [3 ]
Li, J. [2 ]
Li, K. [2 ]
Xu, Y. [2 ]
机构：
[1] Hunan Canc Hosp, Thorac Med Oncol Dept, Changsha, Peoples R China
[2] Hunan Canc Hosp, Dept Thorac Oncol 2, Changsha, Peoples R China
[3] Hunan Canc Hosp, Dept Radiotherapy, Changsha, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574P
引用
收藏
页码：S1695 / S1695
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
    Fang, W.
    Bu, Q.
    Wang, Q.
    Zhao, W.
    Wang, L.
    Dong, X.
    Chen, P.
    Wen, Z.
    Jia, J.
    Jiang, G.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1588
  • [2] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
    Xingxiang Pu
    Yu Zhou
    Yi Kong
    Bolin Chen
    Aifang Yang
    Jia Li
    Kang Li
    Yan Xu
    Lin Wu
    BMC Cancer, 23
  • [3] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
    Pu, Xingxiang
    Zhou, Yu
    Kong, Yi
    Chen, Bolin
    Yang, Aifang
    Li, Jia
    Li, Kang
    Xu, Yan
    Wu, Lin
    BMC CANCER, 2023, 23 (01)
  • [4] Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC and brain metastasis: A multicenter cohort study
    Xing, P.
    Zhou, Y.
    Liu, Z.
    Yao, Y.
    Liu, J.
    Wang, S.
    Hu, Y.
    Li, J.
    Wu, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1695 - S1695
  • [5] Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated
    Fang, W. F.
    Bu, Q.
    Wang, Q. M.
    Zhao, W. H.
    Wang, L. P.
    Dong, X. R.
    Chen, P. F.
    Wen, Z. B.
    Jia, J.
    Jiang, G. M.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S333 - S334
  • [6] Efficacy and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Minemura, H.
    Sugiyama, T.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Minato, K.
    Kaburagi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S943 - S943
  • [7] Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR EXon 20 Insertion Mutations: A Phase 1 Trial
    Duan, Jianchun
    Wu, Lin
    Yang, Kunyu
    Zhao, Jun
    Zhao, Yanqiu
    Dai, Xiumei
    Li, Mingjun
    Xie, Yanyan
    Yao, Yu
    Zhao, Mingfang
    Zhou, Chengzhi
    Ren, Xiubao
    Liu, Zhe
    Pan, Yueyin
    Li, Yuping
    Liu, Baogang
    Cheng, Ying
    Miao, Liyun
    Yu, Qitao
    Zhang, Zhihong
    Liu, Xiaoqing
    Cui, Jiuwei
    Zhang, Yu
    Zhang, Li
    Li, Xiaoyan
    Li, Xiaoling
    Shen, Bo
    Chen, Bi
    Zeng, Shan
    Li, Bin
    Hu, Yanping
    Li, Lin
    Wu, Rong
    Song, Qibin
    Wang, Jie
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (02) : 314 - 324
  • [8] Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
    Han, B.
    Zhang, B.
    Shi, C.
    Gao, Z.
    Zhong, H.
    Xiong, L.
    Gu, A.
    Wang, W.
    Chu, T.
    Zhang, W.
    Wang, H.
    Zhang, X.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [9] Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation
    Wolf, J.
    Heist, R.
    Kim, T. M.
    Nishio, M.
    Dooms, C.
    Kanthala, R. R.
    Leo, E.
    Giorgetti, E.
    Wang, Y.
    Mardjuadi, F. I.
    Cortot, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1007 - S1008
  • [10] Dacomitinib in treatment-naive EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
    Yu, Y.
    Pan, Y.
    Zhou, J.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1694
12345